Results 21 to 30 of about 52,189 (266)

CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality

Scientific Reports, 2023
Tumor-derived extracellular vesicles (EVs) are active contributors in metastasis and immunosuppression in tumor microenvironment. At least some of the EVs carry tumor surface molecules such as tumor-associated antigens (TAAs) and/or checkpoint inhibitors,
V. M. Ukrainskaya, O. E. Musatova, D. V. Volkov, D. S. Osipova, D. S. Pershin, A. M. Moysenovich, E. G. Evtushenko, E. A. Kulakovskaya, E. G. Maksimov, H. Zhang, Y. P. Rubtsov, M. A. Maschan, A. V. Stepanov, A. G. Gabibov   +13 more
doaj   +1 more source

Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display

Journal of Translational Medicine, 2023
Background Monoclonal antibody (mAb)-based immunotherapies have achieved promising outcomes in the treatment of immunological and oncological indications. CD19 is considered one of the most qualified antigens in the treatment of B-cell neoplasms.
Mahmoud Ganji, Pooria Safarzadeh Kozani, Fatemeh Rahbarizadeh   +2 more
doaj   +1 more source

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Frontiers in Oncology
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies.
Yifan Pang, Nilanjan Ghosh
doaj   +1 more source

Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.

PLoS ONE, 2023
T cells genetically engineered to express a chimeric antigen receptor (CAR) specifically binding to a CD19 antigen has become the frontline of hematological malignancies immunotherapy.
Piamsiri Sawaisorn, Korakot Atjanasuppat, Kitipong Uaesoontrachoon, Parin Rattananon, Worapapar Treesuppharat, Suradej Hongeng, Usanarat Anurathapan   +6 more
doaj   +2 more sources

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function

Blood Advances, 2023
Abstract Therapy with CD19-directed chimeric antigen receptor (CAR) T cells has transformed the treatment of advanced B-cell malignancies. However, loss of or low antigen expression can enable tumor escape and limit the duration of responses achieved with CAR T-cell therapy. Engineering bispecific CAR T cells that target 2 tumor antigens
Isabel Leung, Megan L. Templeton, Yun Lo, Anusha Rajan, Sylvia M. Stull, Sarah M. Garrison, Alexander I. Salter, Kimberly S. Smythe, Colin E. Correnti, Shivani Srivastava, Cecilia C. S. Yeung, Stanley R. Riddell   +11 more
openaire   +2 more sources

Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system

Journal for ImmunoTherapy of Cancer
Background A bidirectional promoter-driven chimeric antigen receptor (CAR) cassette provides the simultaneous expression of two CARs, which significantly enhances dual antigen-targeted CAR T-cell therapy.Methods We developed a second-generation CAR ...
Supannikar Tawinwung, Nattiya Hirankarn, Asmita Khaniya, S M Ali Hossieni Rad, Josh Halpin, Alexander McLellan, Koramit Suppipat   +6 more
doaj   +1 more source

A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay

Frontiers in Pharmacology, 2023
Introduction: Cellular immunotherapy has greatly improved cancer treatment in recent years. For instance, chimeric antigen receptor (CAR) T cell therapy has been proven highly effective in treating hematological malignancies, and many CAR cell designs ...
YangHao Fu, TianDuo Wang, John A. Ronald, John A. Ronald   +3 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival

Journal for ImmunoTherapy of Cancer
Background Chimeric antigen receptor (CAR) T-cell therapy is effective in treating B-cell malignancies, however relapse due to lack of CAR persistence and antigen-modulated escape remains common. Multiple strategies to simultaneously target CD19 and CD22
Terry J Fry, Amanda J Novak, Alexander W Rankin, Catherine Pham-Danis, Etienne Danis, M Eric Kohler   +5 more
doaj   +1 more source

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy

Frontiers in Oncology, 2022
BackgroundThe CAR T-cell therapy is a promising approach to treating hematologic malignancies. However, the application in solid tumors still has many tough challenges, including heterogenicity in antigen expressions and immunosuppressive tumor ...
Yuanyuan Liu, Yanxin Zheng, Tianyi Deng, Yue Huang, Ziwen Liu, Borui Zhan, Xusha Zhou, Runbin Yan, Jiangtao Ren, Yun Xing, Guixing Wu, Biao Zheng, Guang Hu, Wen Wang, Yonghong Liu, Jing Zhao, Xiaoqing Chen, Grace Guoying Zhou   +17 more
doaj   +1 more source